Lovastatin Differentially Affects Neuronal Cholesterol and Amyloid-β Production in vivo and in vitro

CNS Neuroscience and Therapeutics

Volumn 21, Issue 8, 2015, Pages 631-641

  Mendoza Oliva, Aydé ^a   Ferrera, Patricia ^a   Fragoso Medina, Jorge ^b   Arias, Clorinda ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

HMGCR; APP; Cholesterol; High fat diet; Lovastatin; SREBP 2

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); HMGCR PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEPTIDE FRAGMENT; SREBF2 PROTEIN, HUMAN; SREBF2 PROTEIN, RAT; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL SURVIVAL; CELL VIABILITY; CEREBELLUM; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID BRAIN LEVEL; MALE; NERVE CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; UPREGULATION; ANIMAL; ANIMAL MODEL; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CEREBRAL CORTEX; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MODELS, ANIMAL; NEURONS; PEPTIDE FRAGMENTS; RATS, SPRAGUE-DAWLEY; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 84937524699     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12420     Document Type: Article

References (76)

1. Ledesma MD, Dotti CG. Peripheral cholesterol, metabolic disorders and Alzheimer's disease. Front Biosci 2012;4:181-194.
2. Kalaria RN. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc Dis 2002;13(Suppl 2):48-52.
3. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002;33:21-25.
4. Jarvik GP, Austin MA, Fabsitz RR, et al. Genetic influences on age-related change in total cholesterol, low density lipoprotein-cholesterol, and triglyceride levels: longitudinal apolipoprotein E genotype effects. Genet Epidemiol 1994;11:375-384.
5. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
7. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000;113(Pt 11):1857-1870.
8. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
9. Vassar R, Bennett BD, Babu-Khan S, et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-741.
10. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994;126:88-94.
11. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000;7:321-331.
12. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain Aβ accumulation in transgenic mice. NeuroReport 2002;13:455-459.
13. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Nat Acad Sci USA 1998;95:6460-6464.
14. Kalvodova L, Kahya N, Schwille P, et al. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 2005;280:36815-36823.
15. Mendoza-Oliva A, Ferrera P, Arias C. Interplay between cholesterol and homocysteine in the exacerbation of amyloid-beta toxicity in human neuroblastoma cells. CNS Neurol Disord Drug Target 2013;12:842-848.
16. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:484-493.
17. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-1631.
18. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443.
19. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004;23:94-98.
20. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Nat Acad Sci USA 2001;98:5856-5861.
21. Scott H. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev 2001; CD003160.
22. McGuinness B. Can statins prevent or help treat Alzheimer's disease? J Alzheimers Dis 2010;20:925-933.
23. Butterfield D. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 2011;64:180-186.
24. Bosel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 2005;92:1386-1398.
25. Bate C, Rumbold L, Williams A. Cholesterol synthesis inhibitors protect against platelet-activating factor-induced neuronal damage. J Neuroinflammation 2007;4:5.
26. Evangelopoulos ME, Weis J, Kruttgen A. Mevastatin-induced neurite outgrowth of neuroblastoma cells via activation of EGFR. J Neurosci Res 2009;87:2138-2144.
27. Pooler AM, Xi SC, Wurtman RJ. The 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal neurons. J Neurochem 2006;97:716-723.
28. Kojro E, Fuger P, Prinzen C, et al. Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-β protein precursor processing by suppression of cholesterol synthesis. J Alzheimers Dis 2010;20:1215-1231.
29. Hoglund K, Thelen KM, Syversen S, et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19:256-265.
30. Won JS, Im YB, Khan M, Contreras M, Singh AK, Singh I. Lovastatin inhibits amyloid precursor protein (APP) β-cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. J Neurochem 2008;105:1536-1549.
31. Hosaka A, Araki W, Oda A, Tomidokoro Y, Tamaoka A. Statins reduce amyloid β-peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterol-independent mechanism in cultured neurons. Neurochem Res 2013;38:589-600.
32. Barone E, Cenini G, Di Domenico F, et al. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res 2011;63:172-180.
33. Kurinami H, Sato N, Shinohara M, et al. Prevention of amyloid β-induced memory impairment by fluvastatin, associated with the decrease in amyloid β accumulation and oxidative stress in amyloid β injection mouse model. Int J Mol Med 2008;21:531-537.
34. Kurata T, Miyazaki K, Kozuki M, et al. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. Neurol Res 2012;34:601-610.
35. Zhang YY, Fan YC, Wang M, Wang D, Li XH. Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease. Clin Interv Aging 2013;8:103-110.
36. Vural K, Tuglu MI. Neurotoxic effect of statins on mouse neuroblastoma NB2a cell line. Eur Rev Med Pharmacol Sci 2011;15:985-991.
37. Michikawa M, Yanagisawa K. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem 1999;72:2278-2285.
38. Tanaka T, Tatsuno I, Uchida D, et al. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. J Neurosci 2000;20:2852-2859.
39. Garcia-Roman N, Alvarez AM, Toro MJ, Montes A, Lorenzo MJ. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol Cell Neurosci 2001;17:329-341.
40. Arnold DE, Gagne C, Niknejad N, McBurney MW, Dimitroulakos J. Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP. Mol Cell Biochem 2010;345:1-11.
41. Marcuzzi A, Tricarico PM, Piscianz E, Kleiner G, Vecchi Brumatti L, Crovella S. Lovastatin induces apoptosis through the mitochondrial pathway in an undifferentiated SH-SY5Y neuroblastoma cell line. Cell Death Dis 2013;4:e585.
42. Ferrera P, Mercado-Gomez O, Silva-Aguilar M, Valverde M, Arias C. Cholesterol potentiates β-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Neurochem Res 2008;33:1509-1517.
43. Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem 2002;76:391-400.
44. Meske V, Albert F, Richter D, Schwarze J, Ohm TG. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci 2003;17:93-102.
45. Schulz JG, Bosel J, Stoeckel M, Megow D, Dirnagl U, Endres M. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem 2004;89:24-32.
46. Kannan M, Steinert JR, Forsythe ID, Smith AG, Chernova T. Mevastatin accelerates loss of synaptic proteins and neurite degeneration in aging cortical neurons in a heme-independent manner. Neurobiol Aging 2010;31:1543-1553.
47. Mailman T, Hariharan M, Karten B. Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol. J Neurochem 2011;119:1002-1015.
48. Mendoza-Oliva A, Zepeda A, Arias C. The complex actions of statins in brain and their relevance for Alzheimer's disease treatment: an analytical review. Curr Alzheimer Res 2014;11:817-833.
49. Wood WGLL, Müller WE, Eckert GP. Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J Neurochem 2014;129:559-572.
50. Botti RE, Triscari J, Pan HY, Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991;14:256-261.
51. Reynolds CP, Biedler JL, Spengler BA, et al. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 1986;76:375-387.
52. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
53. Kruth HS. Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive, oil-red-O-negative particles. Am J Pathol 1984;114:201-208.
54. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
55. Ness GC, Eales S, Lopez D, Zhao Z. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression by sterols and nonsterols in rat liver. Arch Biochem Biophys 1994;308:420-425.
56. Cheng HH, Xu L, Kumagai H, Simoni RD. Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem 1999;274:17171-17178.
57. Maggo S, Ashton JC. Effects of HMG-CoA reductase inhibitors on learning and memory in the guinea pig. Eur J Pharmacol 2014;723:294-304.
58. Hyyppa MT, Kronholm E, Virtanen A, Leino A, Jula A. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial Psychoneuroendocrinology 2003;28:181-194.
59. Matthies H Jr, Schulz S, Hollt V, Krug M. Inhibition by compactin demonstrates a requirement of isoprenoid metabolism for long-term potentiation in rat hippocampal slices. Neuroscience 1997;79:341-346.
60. Linetti A, Fratangeli A, Taverna E, et al. Cholesterol reduction impairs exocytosis of synaptic vesicles. J Cell Sci 2010;123:595-605.
61. Hooff GP, Peters I, Wood WG, Muller WE, Eckert GP. Modulation of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate in neuroblastoma SH-SY5Y-APP695 cells: impact on amyloid β-protein production. Mol Neurobiol 2010;41:341-350.
62. Nieweg K, Schaller H, Pfrieger FW. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem 2009;109:125-134.
63. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipid 2001;12:105-112.
64. Haley RW, Dietschy JM. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol 2000;57:1410-1412.
65. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
66. Puig KL, Floden AM, Adhikari R, Golovko MY, Combs CK. Amyloid precursor protein and proinflammatory changes are regulated in brain and adipose tissue in a murine model of high fat diet-induced obesity. PLoS ONE 2012;7:e30378.
67. Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ. Deposition of iron and β-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem 2006;99:438-449.
68. Thal DR, Rub U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
69. Murphy MP, Morales J, Beckett TL, et al. Changes in cognition and amyloid-β processing with long term cholesterol reduction using atorvastatin in aged dogs. J Alzheimers Dis 2010;22:135-150.
70. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-β production through inhibition of protein isoprenylation. J Biol Chem 2007;282:26832-26844.
71. Cole SL, Vassar R. Isoprenoids and Alzheimer's disease: a complex relationship. Neurobiol Dis 2006;22:209-222.
72. Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H, Vassar R. Statins cause intracellular accumulation of amyloid precursor protein, β-secretase-cleaved fragments, and amyloid β-peptide via an isoprenoid-dependent mechanism. J Biol Chem 2005;280:18755-18770.
73. Papadopoulos P, Tong XK, Hamel E. Selective benefits of simvastatin in bitransgenic APPSwe, Ind/TGF-β1 mice. Neurobiol Aging 2014;35:203-212.
74. Tong XK, Lecrux C, Rosa-Neto P, Hamel E. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J Neurosci 2012;32:4705-4715.
75. Métais C, Brennan K, Mably AJ, Scott M, Walsh DM, Herron CE. Simvastatin treatment preserves synaptic plasticity in AβPPswe/PS1dE9 mice. J Alzheimers Dis 2014;39:315-329.
76. Serrano-Pozo A, Vega GL, Lutjohann D, et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Dis 2010;24:220-226.